Clinicopathological Correlation with Outcome of Diffuse Large B Cell Lymphoma: Experience in a Specialized Cancer Care Centre in Bangladesh

Authors

  • Tamanna Bahar Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh.
  • Zulfia Zinat Chowdhury Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh.
  • Shaila Rahman Department of Medicine, Enam Medical College Hospital, Dhaka, Bangladesh.
  • Salina Haque Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh.
  • AKM Mynul Islam Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh.
  • Mohammad Ali Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh.
  • Md Mahbubur Rahman Department of Haematology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh.

DOI:

https://doi.org/10.3329/jom.v22i1.51383

Keywords:

Diffuse large B-cell lymphoma, non-Hodgkin lymphoma, outcome, Bangladesh

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the world, and accounts for 30%–40% of all adult NHLs. It is clinically, morphologically and genetically a heterogeneous group of tumors composed of large B cells. This study aimed to determine the clinical features, treatment options, the response rate in a specialized cancer care centre.

Methods: This retrospective study included all DLBCL patients registered in the department of Haematology of National Institute of Cancer Research and Hospital (NICR&H), Bangladesh between July 2016 to June 2019.

Results: A total of 151cases were included in this study. The mean age was 47 years with a standard deviation (SD) of 15 years. Males (66.2%) were more in the occurrence of DLBCL. We divided the cases into three different entities of DLBCL and non-germinal centre B (non-GCB) variety was the prevalent (46.4%) one. Several types of first-line chemotherapy were used in management and the overall response rate (ORR) was 76.6% and 9.2% of death. The response was found to be significant with B symptoms, stage, and international prognostic index (IPI) score. But no significant difference was observed in outcome among different types of DLBCL after treatment.

Conclusion: This retrospective study will help to ascertain the co relation of DLBCL outcome with clinicopathological profile. (edited)

J MEDICINE JAN 2021; 22 (1) : 3-6

Downloads

Download data is not yet available.
Abstract
49
PDF
49

Downloads

Published

2021-01-14

How to Cite

Bahar, T., Chowdhury, Z. Z., Rahman, S., Haque, S., Islam, A. M., Ali, M., & Rahman, M. M. (2021). Clinicopathological Correlation with Outcome of Diffuse Large B Cell Lymphoma: Experience in a Specialized Cancer Care Centre in Bangladesh. Journal of Medicine, 22(1), 3–6. https://doi.org/10.3329/jom.v22i1.51383

Issue

Vol. 22 No. 1 (2021)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).